PubMed Health⌕ Search

PubMed · 1836022

Three-dimensional motion and perfusion quantification in gated single-photon emission computed tomograms.

Abstract

Methods for quantification and display of left ventricular (LV) functional parameters from gated single-photon emission computed tomographs are described. Using previously documented surface detection methods, we developed techniques for calculating global variables, such as volumes and areas, as well as local variables such as segmental motion and local perfusion from gated tomographic radionuclide ventriculograms (TRVG) and gated perfusion tomograms (sestamibi). We have developed three-dimensional displays to allow realistic visualizations of the results. The motion results have been validated using correlative magnetic resonance imaging (MRI) studies; motion calculated from user-traced MR images of the heart was compared to motion calculated from automatically detected surfaces in TRVG and sestamibi. The average motion error was calculated to be 0.67 mm in TRVG and -0.21 mm in sestamibi. Errors were largest in basal LV regions; we explain this phenomenon using simulations. Finally, we present additional examples of the analysis using studies obtained from normal volunteers and from subjects whose coronary artery anatomies were known.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T L Faber, M S Akers, R M Peshock, J R Corbett. 1991. Three-dimensional motion and perfusion quantification in gated single-photon emission computed tomograms.. https://pubmed.ncbi.nlm.nih.gov/1836022/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗